Drugs / LauT-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06889766 | Mar 2025 → Jun 2029 expected | metastatic melanoma, sarcoma | Centre Hospitalier Universitaire Vaudois | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LauT-1 | “the patients' own T-cells will be isolated, then genetically modified to express the I53F NY-ESO-1 TCR and expanded to generate the product "LauT-1", which is reinfused into...” NCT06889766 ↗ |
| Action | Deplete | “thereby maximising the chance to detect and potentially eliminate NY-ESO-1 expressing tumor cells” NCT06889766 ↗ |
| Modality | Cell therapy | “Ex vivo expanded autologous CD4+/CD8+ cells expressing the transgenic TCR I53F” NCT06889766 ↗ |
| Route | Intravenous | “On D0, patients will receive NY-ESO-1 TCR T cell infusion, intravenously.” NCT06889766 ↗ |